相关实验视频

Updated: May 7, 2025

Photoacoustic Cystography

Photoacoustic Cystography

Published on: June 11, 2013

探索PACAP在汉纳型间歇性囊炎中的治疗潜力

Hanwei Ke^1,2, Lin Zhu³, Qi Wang^4,5

¹Department of Urology, Peking University People's Hospital, Beijing, 100044, China.

World journal of urology

|January 4, 2025

概括

pituitary adenylate cyclase-activating polypeptide (PACAP) 在亨纳型间歇性囊炎 (HIC) 中升高,并导致炎症和纤维化. 减少PACAP可以缓解这些病理反应,这表明它是HIC的治疗目标.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

亨纳型间歇性囊炎 (HIC) 是一种慢性膀疾病,其特征是炎症和纤维化.
在HIC病原体的基础上,精确的分子机制仍然不完全理解.

研究的目的:

调查垂体腺酸环酶激活聚 (PACAP) 在HIC中的作用.
评估PACAP作为HIC的潜在治疗点.

主要方法:

在HIC患者的膀组织中通过免疫组织化学分析PACAP表达.
使用LPS刺激的SV-HUC1细胞建立一个体外HIC模型.
使用siRNA进行PACAP敲击,以评估对炎症和纤维化标志物 (IL-6,IL-1β,TNF-α,纤维素 1,TGF-β1,原I) 的影响,使用qPCR,西斑和ELISA.
使用伤口愈合和CCK-8试验分析细胞迁移和增殖.
转录形状分析以识别差异表达的基因.

主要成果:

在HIC膀组织中,PACAP的表达显著上调.
在体外,LPS刺激增加了PACAP,炎症性细胞因子和纤维化标志物.
PACAP的敲击抑制了炎症和纤维化,并抑制了细胞迁移和增殖.
转录基因分析证实了PACAP在HIC病变发生过程中的参与.

结论:

在HIC的炎症和纤维化途径中,PACAP起着至关重要的作用.
针对PACAP可以缓解与HIC相关的病理反应.
PACAP代表了一个有前途的新型治疗点HIC.

关键词:

亨纳型的间歇性囊炎 (HIC)炎症炎症是一种炎症.这就是PacaPap的意义.治疗目标治疗目标转录组分析转录组分析

更多相关视频

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...